RAPT Therapeutics (RAPT) Reports Complete Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis
Go back to RAPT Therapeutics (RAPT) Reports Complete Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis| Raptor Technology Group, Inc. (NASDAQ: RAPT) | Delayed: 7.80 -0.1 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.90 | 52 Week High | $0.02 | |||
| Open | $7.82 | 52 Week Low | $0.00 | |||
| Day High | $7.92 | P/E | N/A | |||
| Day Low | $7.52 | EPS | $0.00 | |||
| Volume | 420,016 | |||||
